Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum

Simply Wall St.01-11

CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602347845?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-11 07:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602347845","market":"hk","top_or_hot":-1,"title":"Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/assessing-cg-oncology-cgon-valuation-after-strong-recent-sha\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 07:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/assessing-cg-oncology-cgon-valuation-after-strong-recent-sha><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/assessing-cg-oncology-cgon-valuation-after-strong-recent-sha\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/assessing-cg-oncology-cgon-valuation-after-strong-recent-sha","article_id":"2602347845","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/assessing-cg-oncology-cgon-valuation-after-strong-recent-sha","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602347845","pubTimestamp":1768087595,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent clinical progress.\nSee our latest analysis for CG Oncology.\nThe latest move sits on top of strong recent momentum, with a 1 day share price return of 29.26%, a 30 day share price return of 29.85% and a 1 year total shareholder return of 79.47%. Together, these figures suggest that investors are...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CG":"凯雷","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","CGON":"CG Oncology Inc.","BK4135":"资产管理与托管银行"},"translate_title":"在近期股价强劲势头后评估CG Oncology(CGON)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGON":1.5,"DCF":1,"CG":1.5},"content_text":"CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent clinical progress. See our latest analysis for CG Oncology. The latest move sits on top of strong recent momentum, with a 1 day share price return of 29.26%, a 30 day share price return of 29.85% and a 1 year total shareholder return of 79.47%. Together, these figures suggest that investors are reassessing CG Oncology’s prospects and risk profile. If CG Oncology’s surge has caught your attention, it could be a good moment to see what else is happening across healthcare stocks for more cancer and healthcare names on your radar. With CG Oncology still loss making on just US$2.17m of revenue, yet trading at US$54.20 and sitting below an average analyst price target, you have to ask: is there genuine upside here, or is the market already pricing in future growth? AdvertisementPrice to Book of 6.4x: Is it justified? CG Oncology’s current share price of US$54.20 lines up with a P/B ratio of 6.4x, which screens as relatively expensive against the broader US biotech space but sits below its closer peer set. P/B compares the company’s market value to its net assets on the balance sheet. It is often used for early stage or loss making biopharma names where earnings based metrics such as P/E are not meaningful. In CG Oncology’s case, the P/B of 6.4x is higher than the US biotech industry average of 2.7x. This suggests the market is paying a premium for its bladder cancer pipeline and future potential despite current losses and limited revenue of US$2.17m. At the same time, that 6.4x multiple sits below the peer average of 8.8x. While the stock trades rich to the sector overall, it is being valued more conservatively than a tighter peer group that the SWS model uses for comparison. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to Book of 6.4x (ABOUT RIGHT) However, you are still looking at a loss of US$151.48m on just US$2.17m of revenue, and trial setbacks or delays could quickly challenge today’s premium. Find out about the key risks to this CG Oncology narrative. Another view: DCF paints a very different picture While the 6.4x P/B suggests CG Oncology is expensive against the broader biotech group, our DCF model points the other way, with an estimate of fair value at US$292.60 per share versus the current US$54.20. That is a very large gap for you to weigh up. Look into how the SWS DCF model arrives at its fair value. CGON Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 876 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own CG Oncology Narrative If you see the numbers differently or simply prefer to piece together your own view from the data, you can build a personalised thesis in minutes: Do it your way. A great starting point for your CG Oncology research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If CG Oncology sits on your watchlist, do not stop there. Widen your opportunity set with focused stock ideas filtered by fundamentals, themes, and income potential.  Spot potential high risk high reward ideas early by scanning these 3540 penny stocks with strong financials that already clear basic financial quality checks. Ride the momentum of digital transformation by zeroing in on these 28 AI penny stocks at the intersection of artificial intelligence and rapid growth themes. Strengthen your core watchlist by filtering for these 876 undervalued stocks based on cash flows that may trade below what their cash flows suggest.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602347845","isCrawlerRequest":true}